Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-23
2011-08-23
Sznaidman, Marcos (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S215000, C514S247000, C514S278000, C514S297000
Reexamination Certificate
active
08003632
ABSTRACT:
A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.
REFERENCES:
patent: 4550113 (1985-10-01), Lavretskaya et al.
patent: 4562196 (1985-12-01), Horn et al.
patent: 4631286 (1986-12-01), Shutske et al.
patent: 4754050 (1988-06-01), Shutske et al.
patent: 4816456 (1989-03-01), Summers
patent: 4831155 (1989-05-01), Brufani et al.
patent: 4835275 (1989-05-01), Shutske et al.
patent: 4839364 (1989-06-01), Shutske et al.
patent: 4868177 (1989-09-01), Shutske et al.
patent: 4895841 (1990-01-01), Sugimoto et al.
patent: 4914102 (1990-04-01), Glamkowski
patent: 4948807 (1990-08-01), Rosin et al.
patent: 4950653 (1990-08-01), Jauw
patent: 4950658 (1990-08-01), Becker et al.
patent: 4978155 (1990-12-01), Kobayashi
patent: 5081117 (1992-01-01), Glamkowski et al.
patent: 5100901 (1992-03-01), Sugimoto et al.
patent: 5104880 (1992-04-01), Kozikowski
patent: 5185350 (1993-02-01), Effland et al.
patent: 5254548 (1993-10-01), Wermuth et al.
patent: 5306825 (1994-04-01), Brufani et al.
patent: 5397785 (1995-03-01), Ninomiya et al.
patent: 5536728 (1996-07-01), Ninomiya et al.
patent: 5554780 (1996-09-01), Wolf
patent: 5693668 (1997-12-01), Schirlin et al.
patent: 5760267 (1998-06-01), Gandolfi et al.
patent: 5861411 (1999-01-01), Ninomiya et al.
patent: 5929084 (1999-07-01), Zhu et al.
patent: 5981549 (1999-11-01), Viner
patent: 6194403 (2001-02-01), Hu et al.
patent: 6433173 (2002-08-01), Omori
patent: 6610713 (2003-08-01), Tracey
patent: 6838471 (2005-01-01), Tracey
patent: 2003/0139391 (2003-07-01), Parys et al.
patent: 2004/0214863 (2004-10-01), Pratt
patent: 0 633 251 (1995-01-01), None
patent: 57114512 (1982-07-01), None
patent: WO 98/00119 (1998-01-01), None
patent: WO 99/08672 (1999-02-01), None
patent: WO 01/89526 (2001-11-01), None
patent: WO 2004/034963 (2004-04-01), None
Rees et. al. , Cardiovascular Research (1993) 27:453-458.
Rees et. al. (Cardiovascular Research (1993) 27:453-458).
Leone et. al. (Expert Opinion on Emerging Drugs (2010)15:41-52).
Aboab (Expert Opinion on Emerging Drugs (2006) 11:7-22).
Greenlee, W., et al., “Muscarinic Agonists and Antagonists in the Treatment of Alzheimer's Disease,” IL Farmaco, 56:247-250 (2001).
Bruhwyler, J., et al., “Multicentric Open-Label Study of the Efficacy and Tolerability of Citicoline in the Treatment of Acute Cerebral Infarction,”Current Therapeutic Research, 55: 5, pp. 309-316 (May 1997).
Freeman, S., et al., “Tacrine: A Pharmacological Review,”Progress in Neurobiology, 36: pp. 257-277, (1991).
Rees, S., et al., “Tacrine Inhibits Ventricular Fibrillation Induced by Ischaemia and Reperfusion and Widens QT Interval in Rat,”Cardiovascular Research, pp. 453-458 (1993).
Zemlan, F.P., et al., “Double-Blind Placebo-Controlled Study of Velnacrine in Alzheimer's Disease,”Life Sciences, 58: 21, pp. 1823-1832 (1996).
Pavlov, V., et al., “The Cholinergic Anti-Inflammatory Pathway: A Missing Link in Neuroimmunomodulation,”Molecular Medicine, 9: 5-8, pp. 125-134 (May-Aug. 2003).
Buerkle, H., et al., “Central and Peripheral Analgesia Mediated by the Acetylcholinesterase-Inhibitor Neostigmine in the Rat Inflamed Knee Joint Model.”Anesthesia and Analgesia, 86:1027-1032 (1998).
Patocka, J., et al., “Huperzine A—An Interesting Anticholinesterase Compound From the Chinese Herbal Medicine,”ACTA Medica, 41(4): 155-157 (1998).
Behling, A., et al., “Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure,”American Heart Journal, 146(3): 494-500 (2003).
Cozanitis, D.A., et al., “A Cinebronchographic Study Demonstrating the Effect of Galanthamine Hydrobromide on Conscious Asthmatic Volunteers,”der Anaesthesist, 21(1): 63-66 (1972).
Ponce, R. J., et al., “Neostigmine for the Treatment of Acute Colonic Pseudo-Obstruction,”The New England Journal of Medicine, 341(3): 137-141 (1999).
Breccia, M., et al., “Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine,”Annals of Hematology, 80:614-616 (2001).
Vesentini, S., et al., Effects of Choline-Esterase Inhibitor in Experimental Acute Pancreatitis in Rats,International Journal of Pancreatology, 13(3): 217-220 (1993).
Debord, J., et al., Cholinesterase Inhibition by Derivatives of 2-Amino-4,6-Dimethylpyridine,J. Enzyme Inhibition, 12:13-26 (1997).
Nakayama, et al., “Sepsis attenuates the intensity of the neuromuscular blocking effect of d-tubocurarine and the antagonistic actions of neostigmine and edrophonium accompanying depression of muscle contractility of the diaphragm,”Acta Anaesthesiol Scand, 43(2):196-201(1999).
Yoshiyama Y. et al., “Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopat mouse model”, J Alzheimers Dis. 2010; 22 (1): 295-306 (Abstract).
Pavlov Valentin A.
Tracey Kevin J.
Riverside Law LLP
Sznaidman Marcos
The Feinstein Institute for Medical Research
LandOfFree
Cholinesterase inhibitors for treating inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cholinesterase inhibitors for treating inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cholinesterase inhibitors for treating inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2730242